A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs Omipalisib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 16 Aug 2016 Status changed from recruiting to completed.
- 21 Apr 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016.